In vivo animal studies with sugammadex.
A review is presented of animal studies of the selective steroidal neuromuscular blocking drug binding agent sugammadex. These studies demonstrate that sugammadex is faster in onset than the currently used acetylcholinesterase inhibitors, has no muscarinic effects, and is characterised by lack of adverse effects on other organs. These results offer support for the further development of sugammadex for clinical use in humans.
Booij
L H D J
LH
Department of Anaesthesiology, Radbound University Medical Center, Nijmegen, The Netherlands. l.booij@owi.umcn.nl
van Egmond
J
J
Driessen
J J
JJ
de Boer
H D
HD
D000762:Anesthesia Recovery Period; D000818:Animals; D019148:Neuromuscular Blockade / Q000379:methods; D009469:Neuromuscular Junction / Q000187:drug effects; D003473:Neuromuscular Nondepolarizing Agents / Q000037:antagonists & inhibitors*; D000077122:Sugammadex; D047408:gamma-Cyclodextrins / Q000009:adverse effects / Q000494:pharmacology*
D003473:Neuromuscular Nondepolarizing Agents; D047408:gamma-Cyclodextrins; D000077122:Sugammadex